The global clinical genomics market is set to grow from USD 1.06 billion in 2024 to an impressive USD 5.34 billion by 2034, reflecting a robust compound annual growth rate (CAGR) of 17.54%. This remarkable expansion is driven by increasing incidences of genetic and rare diseases, as well as ongoing innovations in molecular diagnostic testing.
The increasing burden of hereditary and rare disorders is significantly boosting the demand for clinical genomics. These technologies offer faster and more precise diagnostics compared to traditional methods, supporting their growing use in early diagnosis and personalized medicine. North America is leading the market, but Asia Pacific is catching up fast due to growing healthcare investments and R&D activities.
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/download-databook/5754
The market size in 2024 is projected at USD 1.06 billion.
Expected to reach USD 5.34 billion by 2034.
CAGR of 17.54% from 2025 to 2034.
North America holds the largest share of the market.
Asia Pacific is anticipated to grow at the fastest rate.
Diagnostic testing dominates the test type segment.
Genetic testing is forecast to grow the fastest within test types.
Biochemical tests currently lead the method type category.
Molecular tests are expected to be the fastest-growing method type.
Hospitals and clinics lead among end users, while academic and research institutes are projected to grow rapidly.
Clinical genomics involves using next-generation sequencing (NGS) to gather information from the genome, epigenome, and transcriptome. By applying techniques like whole-genome sequencing and exome sequencing, this field supports diagnosis, screening, and treatment planning for conditions like cancer, neurological disorders, and chronic illnesses. It’s also a cornerstone of the expanding field of precision medicine.
Get All the Details in Our Solutions – Access Report Preview: https://www.towardshealthcare.com/download-sample/5754
June 2025: GenePoweRx and MGI Tech announced a partnership to enhance AI-based genomic solutions, targeting more accessible and predictive healthcare.
March 2025: Illumina Inc. and Nashville Biosciences revealed their sequencing of 250,000 genomes as part of the Alliance for Genomic Discovery to drive therapeutic research.
Artificial intelligence is being used to revolutionize genomics data analysis and accelerate drug discovery. It helps predict disease phenotypes, streamline treatment personalization, and enhance the interpretation of complex genetic data—ultimately improving patient outcomes while reducing healthcare costs.
If you have any questions, please feel free to contact us at sales@towardshealthcare.com
With a steady rise in genetic and rare diseases, clinical genomics is emerging as a vital tool for early detection and treatment selection. Its non-invasive nature also makes it popular for newborn screening.
Despite its benefits, clinical genomics remains costly due to the need for advanced infrastructure, skilled professionals, and complex data interpretation. Regulatory hurdles further contribute to the financial burden, limiting accessibility for some patients.
The landscape is evolving with techniques like CRISPR-based diagnostics, PCR, and microfluidics. AI integration is also enabling non-invasive approaches like liquid biopsy to gain traction, expanding the market’s potential.
April 2025 Milestone: HaystackAnalytics received NABL accreditation for its genomics-based diagnostics lab in India, marking a significant boost for molecular testing in the region.
Diagnostic testing led the market in 2024 due to its widespread use in accurately diagnosing diseases. Meanwhile, genetic testing is expected to see rapid growth fueled by increased awareness and the rising incidence of genetic disorders.
Biochemical tests dominated in 2024, especially for newborn and metabolic disorder screenings. Molecular tests are gaining ground due to their effectiveness in cancer and infectious disease diagnosis, supported by continuous technological advancement.
Hospitals and clinics accounted for the largest share in 2024, largely because of the high volume of patient testing and skilled workforce availability. However, academic and research institutes are emerging as high-growth players due to increased R&D funding and innovation incentives.
North America’s robust healthcare system, skilled personnel, and cutting-edge technologies made it the top regional market in 2024. The U.S., in particular, is seeing rising AI integration into genomics platforms, enhancing diagnosis and research.
Increased awareness of genetic diseases and emphasis on precision medicine are propelling Canada’s clinical genomics market forward, particularly in the research community.
Rapid healthcare expansion, increasing R&D investments, and tech adoption are making Asia Pacific the fastest-growing region in the market.
China: Expanding its capabilities in early disease diagnosis and improving data analytics in genomics.
India: A surge in diseases and awareness is encouraging government-backed R&D and private investments.
Europe is experiencing significant growth in clinical genomics thanks to increasing demand for non-invasive and accurate diagnostics. Germany stands out with its strong regulatory compliance and integration of genetic testing into mainstream healthcare.
May 2025: Bioheaven360 Genotec launched an AI-driven genomic diagnostics platform in India to reshape preventive healthcare and empower patients through data-driven health insights.
April 2025: NeoGenomics partnered with Ultima Genomics to accelerate NGS-based precision oncology tools, aiming to translate innovations into impactful patient care.
June 2025: BioAro introduced a major update to its AI-powered PanOmiQ Research platform at the BIO International Convention, further enhancing its drug discovery and multi-omics capabilities.
May 2025: Mapmygenome, a leader in personalized health, acquired Microbiome Insights, a Canadian CAP-accredited lab, to strengthen its molecular diagnostics portfolio.
Source : https://www.towardshealthcare.com/insights/clinical-genomics-market-sizing
The global single-cell biotherapeutics market is on a robust growth trajectory, with projections indicating a surge into the hundreds of… Read More
The global multiomics in drug discovery market is undergoing transformative growth, with projections pointing toward a significant surge in revenue… Read More
The global healthcare ecosystem is undergoing a profound transformation. One of the most pivotal shifts is the surge in demand… Read More
The global AI in medical billing market is undergoing a significant transformation, poised to grow from USD 3.73 billion in… Read More
The global preclinical advanced cell models market is rapidly evolving, fueled by the increasing demand for accurate, human-relevant testing platforms… Read More
The digital revolution is reshaping healthcare education across the globe. With the integration of virtual platforms, AI, and immersive technologies,… Read More